Business
Theralase's Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World Congress
TORONTO, ON / ACCESSWIRE / MARCH 26, 2019 / Theralase Technologies Inc. (" Theralase ® ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase’s Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World CongressTORONTO, ON / ACCESSWIRE / MARCH 26, 2019 /Theralase Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (\"PDC\") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association (\"IPA\") World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019.IPA has been bringing together researchers and clinicians in all fields of PhotoDynamic Therapy (\"PDT\") and PhotoDiagnosis (\"PD\") since 1986. Every two years, the IPA organizes a conference to foster scientific development and contribute to clinical practice, ultimately capturing the current status of the field.This year, Lother Lilge, Ph.D., Professor of Medical Biophysics at the University of Toronto, an esteemed PDT expert and a member of the Medical and Scientific Advisory Board (\"MSAB\"), was elected to be a Co-Chairman of the Urology Session at the Congress and has been invited to deliver a presentation entitled, \"Improving the Safety and Efficacy of PhotoDynamic Therapy of Bladder Cancer – Light Dosimetry Aspects of a Phase Ib Study Using Intravesical TLD-1433 (a Ruthenium (II)-Based Photosensitizer) in Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients\". Dr. Lilge's presentation will focus on the laser dosimetry utilized and clinical outcomes of the Study. In addition, Dr. Lilge will discuss applications of Theralase's Anti-Cancer Technology (\"ACT\") to other cancers, as well as the potential for a combination of Theralase's lead PDC, TLD-1433, with various physical therapeutic modalities.Shawn Shirazi, Ph.D., CEO – Drug Division, Theralase stated \"I'm delighted that the data pertaining to the Study has been elected for the invited talk by the IPA. One of the advances and inventive steps of the TLD-1433 ACT in patients with NMIBC is the ability to optimize the light delivery during the PDT process. I believe that controlling the PDT laser light energy during PDT treatment...